2024
Quantification of Cinpanemab (BIIB054) Binding to α-Synuclein in Cerebrospinal Fluid of Phase 1 Single Ascending Dose Samples
Liu Y, Yang M, Fraser K, Graham D, Weinreb P, Weihofen A, Hirst W, Cedarbaum J, Pepinsky B. Quantification of Cinpanemab (BIIB054) Binding to α-Synuclein in Cerebrospinal Fluid of Phase 1 Single Ascending Dose Samples. Journal Of Pharmacology And Experimental Therapeutics 2024, jpet-ar-2024-002199. PMID: 38936981, DOI: 10.1124/jpet.124.002199.Peer-Reviewed Original ResearchCentral nervous systemCerebrospinal fluidMeso Scale DiscoveryCentral nervous system compartmentDrug concentrationsA-synCerebrospinal fluid samplesParkinson's diseasePassive immunotherapy approachesSite of actionImmunotherapy approachesLow drug concentrationsImmunotherapy trialsHealthy volunteersSystemic compartmentDrug-target interactionsCSF samplesObserved doseNervous systemTherapeutic targetA-syn levelsClinical samplesTime-dependent bindingComplex formationCross-linking method
2015
Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology
Cedarbaum JM, Stephenson D, Rudick R, Carrillo MC, Stebbins G, Kerr D, Heemskerk J, Galpern WR, Kaufmann P, Cella D, Isaac M, Walton MK. Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology. Neurotherapeutics 2015, 12: 151-169. PMID: 25384682, PMCID: PMC4322066, DOI: 10.1007/s13311-014-0310-1.Peer-Reviewed Original ResearchConceptsOutcome measuresNeurological disordersDisease-specific outcome measuresClinical trial measuresAssessment of dysfunctionAutonomic system functionMotor functionNervous systemRelated disordersDisordersDisease areasAmerican SocietyDrug developmentDysfunctionTrial measuresTerms of cognitionNeurologyAssessment developmentSystem functionAnnual MeetingNeurologistsSymptomsNeurotherapeutics
1996
Chapter 10 Neurotrophic factors Towards a restorative therapy of Parkinson's disease
Altar C, Wiegand S, Lindsay R, Cedarbaum J. Chapter 10 Neurotrophic factors Towards a restorative therapy of Parkinson's disease. 1996, 159-185. DOI: 10.1016/b978-012525445-8/50012-6.ChaptersNeurotrophic factorBasic fibroblast growth factorRestorative therapyGrowth factorParkinson's diseaseNervous systemBasal forebrain cholinergic neuronsBrain-derived neurotrophic factorForebrain cholinergic neuronsPeripheral nervous systemFibroblast growth factorCholinergic neuronsNeurotrophin-4/5GABAergic systemPeripheral nervesTrophic actionGlial cellsSerotonergic neuronesNonneural tissuesFiring rateNeuronesDiseaseBiological actionsSecond groupTherapy
1991
Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys: Implications for the Treatment of Parkinson's Disease.
Cedarbaum J, Leger G, Guttman M. Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys: Implications for the Treatment of Parkinson's Disease. Clinical Neuropharmacology 1991, 14: 330. PMID: 1913700, DOI: 10.1097/00002826-199108000-00005.Peer-Reviewed Original ResearchTemporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease
Olanow CW, Gauger LL, Cedarbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Annals Of Neurology 1991, 29: 556-559. PMID: 1859185, DOI: 10.1002/ana.410290516.Peer-Reviewed Original ResearchConceptsVentricular cerebrospinal fluidCerebrospinal fluidParkinson's diseasePlasma levodopa concentrationsAdvanced Parkinson's diseaseCerebrospinal fluid pharmacokineticsPharmacokinetics of levodopaCentral nervous systemLevodopa levelsOmmaya reservoirClinical effectsLevodopa effectsParkinsonian patientsLevodopa concentrationsHomovanillic acidNervous systemDrug concentrationsLevodopaDiseaseMotor performancePatientsTime coursePharmacokineticsTemporal relationshipNucleus transplantation
1986
Mitochondrial dysfunction and spinocerebellar degenerations
Cedarbaum J, Blass J. Mitochondrial dysfunction and spinocerebellar degenerations. Journal Of Molecular Neuroscience 1986, 4: 43-63. PMID: 3520401, DOI: 10.1007/bf02834298.Peer-Reviewed Original ResearchConceptsSpinocerebellar degenerationProminent clinical featureMitochondrial damageMultiple system degenerationClinical featuresPathophysiological mechanismsOlivopontocerebellar atrophyDiffuse diseaseSystem degenerationNervous systemRelated disordersLong axonsObserved pathologyAtaxiaDegenerationMitochondrial dysfunctionSimplified classificationFriedreich's ataxiaCommon mechanism